Meeting
2024 ASCO Annual Meeting
Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.
Authors
Manish Sharma
START Midwest, Grand Rapids, MI
Manish Sharma , Anne M. Noonan , Daniel A. Vaena , Ecaterina Elena Dumbrava , Judy S. Wang , Drew W. Rasco , Kyriakos P. Papadopoulos , Aditya V. Shreenivas , Pierre Ferre , Eran Ophir , Inbal Barbiro , Gady Cojocaru , Michelle Mahler , Adeboye H. Adewoye , Manish R. Patel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Clinical Trial Registration Number
NCT04354246.
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 3597)
DOI
10.1200/JCO.2024.42.16_suppl.3597
Abstract #
3597
Poster Bd #
260
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
First Author: Drew W. Rasco
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi
Poster
2024 ASCO Genitourinary Cancers Symposium
Preclinical testing of a novel PD-L1 inhibitor for the treatment of renal cell carcinoma.
First Author: Michelle Hsu